GlassScriptPhysician profile
Evelyn J Jackson
NPI 1770707093
$2,609.89
in general payments reported to CMS, 2019-2025
24 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $319 · 2021: $527 · 2022: $546 · 2023: $315 · 2024: $301 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.68 | 2019-2024 | |
| Novo Nordisk INC | $395.94 | 2019-2023 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $352.07 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $255.36 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $204.49 | 2021-2025 | |
| Lilly USA, LLC | $196.08 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $185.54 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $71.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $64.42 | 2022 | |
| Glaxosmithkline, LLC. | $57.44 | 2021-2025 | Arexvy, Shingrix |
| Radius Health, INC. | $54.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.47 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $41.28 | 2021-2022 | |
| Esperion Therapeutics, INC. | $36.97 | 2023 | Nexletol |
| Abbott Laboratories | $33.58 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $29.08 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $20.04 | 2021 | |
| Eisai INC. | $18.16 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.78 | 2022 | |
| Bausch Health US, LLC | $15.32 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Sanofi Pasteur INC. | $13.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.